Ropes & Gray advised EQRx in a strategic drug creation, development, and commercialization collaboration with Exscientia. The transaction was announced on June 24.
The collaboration combines Exscientia’s leading AI-driven drug discovery capabilities and EQRx’s innovative development and commercialization model to accelerate the delivery of new medicines to more patients at lower prices with drug candidates in multiple therapeutic areas, including oncology and immunology, expanding EQRx’s pipeline of novel therapies.
Under the terms of the agreement, Exscientia will lead the discovery phase until Investigational New Drug application (IND) filing, while EQRx will be responsible for clinical development, regulatory and commercialization efforts. EQRx and Exscientia will equally share in the discovery, development and commercialization costs.
The Ropes & Gray team was led by life sciences partner Abigail Gregor.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.